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Anthracyclines are widely used in paediatric oncology, but their use is limited by the risk of cumulative cardiac toxicity. Encapsulating
anthracyclines in liposomes may reduce cardiac toxicity and possibly increase drug availability to tumours. A phase I study in paediatric
patients was designed to establish the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) after a single course of
liposomal daunorubicin, ‘DaunoXome’, as a 1h infusion on day 1 of a 21 day cycle. Patients were stratified into two groups according
to prior treatment: Group A (conventional) and group B (heavily pretreated patients). Dose limiting toxicity was expected to be
haematological, and a two-step escalation was planned, with and without G-CSF support. Pharmacokinetic studies were carried out in
parallel. In all, 48 patients aged from 1 to 18 years were treated. Dose limiting toxicity was neutropenia for both groups. Maximum
tolerated dose was defined as 155mgm
 2 for Group A and 100mgm
 2 for Group B. The second phase with G-CSF was
interrupted because of evidence of cumulative cardiac toxicity. Cardiac toxicity was reported in a total of 15 patients in this study.
DaunoXome shares the early cardiotoxicity of conventional anthracyclines in paediatric oncology. This study has successfully defined
a haematological MTD for DaunoXome, but the significance of this is limited given the concerns of delayed cardiac toxicity. The
importance of longer-term follow-up in patients enrolled into phase I studies has been underestimated previously, and may lead to an
under-recognition of important adverse events.
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Anthracycline antibiotics have a wide spectrum of activity, and are
used in many adult and paediatric protocols for the treatment
of haematological and solid malignancies. The risk of cardiomyo-
pathy is dose-limiting, and is related to cumulative dose, young
age, mediastinal radiotherapy and pre-existing cardiac impairment
(Von Hoff et al, 1977, 1979; Steinherz et al, 1991; Pein et al, 2004).
It may appear early or late, and major concerns have been raised
by long-term follow-up studies of children treated early in their life
(Poutanen et al, 2003; Pein et al, 2004). Strategies to reduce this
risk have included limitation of the total administered dose,
administration in fractionated rather than single doses, as
infusions, the use of protective agents and liposomal encapsulation
of the compound (Weiss and Manthel, 1977).
The effect of administration schedule of anthracyclines – as a
bolus or as a prolonged infusion – has been studied in preclinical
models and clinically. The pharmacokinetics of doxorubicin do
appear to be affected by infusion duration (Cusack et al, 1993),
with a reduction of cardiac exposure after a prolonged exposure
(Cusack et al, 2003), and a beneficial effect of prolongation
identified in some cases (Casper et al, 1991; Gupta et al, 2003) but
not all (Speyer et al, 1985; Hortobagyi et al, 1989; Zalupski et al,
1991; Levitt et al, 2004). Similarly, the evidence for the use of
cardioprotectants is mixed, and improved cardiotoxicity may be
achieved at the expense of a reduced response rate (reviewed by
van Dalen et al (2005)).
Liposomal encapsulation may lead to changes in the pharmaco-
kinetics of the anthracycline, and this may increase delivery to the
tumour and reduce that to healthy tissues. The anthracycline
within DaunoXome (
s, daunorubicin) is held within a vesicle
comprising disteroyl phosphatidyl choline (DSPC) and cholesterol.
Vesicles of this diameter (40–60nm) are not rapidly cleared from
the plasma by the reticulo-endothelial system, and release of
daunorubicin continues in a sustained manner. Preclinical studies
indicate increased tissue concentrations of daunorubicin in
tumour, brain, liver, spleen and intestine following DaunoXome
compared with free daunorubicin administration, but a reduced
tissue concentration in cardiac tissue (AUC ratio 0.4) (Forssen and
Ross, 1994). In addition, studies using radio-labelled vesicles
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ssuggest selective uptake into tumour (Forssen et al, 1992). An
improved therapeutic index is therefore expected. In a murine
lymphosarcoma model, significantly longer survival was seen in
mice treated with DaunoXome than with free daunorubicin
(Forssen and Ross, 1994).
Previous adult studies have reported acceptable toxicity with
doses in excess of 100mgm
 2 (Eckardt et al, 1994; Guaglianone
et al, 1994; Richardson et al, 1997; McBride et al, 2001). Most
clinical studies with DaunoXome have been in adult patients, and
cardiac toxicity has not been a prominent feature even with
cumulative doses of over 1000mgm
 2, although follow-up of
patients was short (Money-Kyrle et al, 1993; Presant et al, 1993;
Guaglianone et al, 1994; Gill et al, 1995).
A French phase I study of DaunoXome in children with acute
lymphoblastic leukaemia, delivered DaunoXome every 7 days for
4 weeks at a starting dose of 40mgm
 2 and did not reach an
maximum tolerated dose (MTD). The maximum cumulative dose
of anthracyclines was 720mgm
 2: only one patient, treated at the
first level of 40mgm
 2, showed a decrease in fractional shortening
of more than 10%. Owing to relapse or death, cardiac data are
available in only 16 patients and all have normal function,
although the assessment of cardiac function was made early post-
treatment (A Baruchel, Personal communication).
A phase I study with a similar schedule in children with
recurrent or progressive brain tumours reported encouraging
activity (Lippens, 1999). Patients received DaunoXome as a 1h
infusion at a dose of 60mgm
 2, once every 4 weeks. Two patients
had received prior anthracycline, but neither developed cardiac
toxicity. Cardiac toxicity was seen in three of 14 children. One
patient developed cardiac toxicity with a fall in FS to 20%. This
patient had received prior radiotherapy to the spine (35Gy), which
had included some cardiac tissue, but toxicity was not identified
until after the eighth course of DaunoXome. Two other patients
developed transient reductions in FS to o28% after four and seven
cycles, but in both, DaunoXome administration was continued and
FS said to recover to normal values. An average transient reduction
in the thickness of the posterior wall and septum was reported, but
this too recovered within 6 months of cessation.
Overall, there seemed to be reasonable evidence to suggest that
DaunoXome might offer good efficacy with acceptable toxicity.
There seemed to be evidence of reduced cardiac toxicity to allow
dosing beyond the conventional limit of 550mgm
 2, and we
decided therefore to undertake a phase I study of DaunoXome in
children with relapsed or resistant malignant solid tumours.
STUDY AIMS
The primary aims of the study were to determine:
(1) the dose limiting toxicity (DLT) and MTD of DaunoXome
when given as a single infusion over 1h to children with
relapsed or resistant solid tumours in two cohorts, one having
received conventional therapy and the other prior craniospinal
radiotherapy or high-dose therapy;
(2) a second DLT and MTD in each cohort of patients with G-CSF
support using the MTD from the previous study;
(3) the pharmacokinetics of liposomal daunorubicin in children.
The secondary aim was to document tumour response in these
patients.
STUDY DESIGN
Patient eligibility
The study was open from December 1998 to June 2001 as a joint
UK/French study. All centres participating were required to fulfil
UKCCSG/SFOP criteria for phase I studies. Patients with recurrent
or resistant malignant disease, aged between 1 and 18 years, with
a predicted life expectancy of more than 8 weeks, and a
performance status score (Karnofsky 430 or Lansky 43) were
eligible for entry.
ECG, two-dimensional echocardiogram with documentation of
Fractional Shortening and ejection fraction and a chest radiograph
were recorded at entry. ECG and two-dimensional echocardiogram
were repeated prior to each subsequent course of chemotherapy.
Normal cardiac function, with a fractional shortening X29% was
required at entry into the study. A reduction of FS to o29% or a
reduction of EF by more than 20% were used to define toxicity
according to CTC criteria.
Laboratory investigations (creatinine, urea and electrolytes,
calcium, magnesium, phosphate, alkaline phosphatase, alanine
transaminase, albumin, bilirubin, full blood count with differential
WBC and coagulation screen) were performed within 7 days of
DaunoXome administration to ensure adequate haematological,
renal and hepatic function, and were repeated prior to each
subsequent course of chemotherapy.
Written informed consent was given by all parents or guardians,
and by patients themselves where appropriate. In the UK, this
study was approved by the Multi-Centre Research Ethics
Committee for Scotland and by Local Research Ethics Committees
of each participating centre. In France, approval was received from
the CCPPRB (Comite ´ Consultatif de Protection des Personnes dans
la Recherche Biomedicale) with Centre Le ´on Be ´rard in Lyon acting
as promoter. Study monitoring and Source Data Verification were
performed according to ICH GCP guidelines.
Study administration and drug supply
In all, 17 centres (12 UK, five French) were eligible to enter patients
into the study. Coordination of the study was through the UKCCSG
Data Centre. Once three patients were recruited at a dose level,
recruitment was frozen to allow all those patients to complete their
first cycle (30 days to allow for toxicities) and be monitored.
Monitoring was organised by the UKCCSG Data Centre. Dauno-
Xome was kindly supplied by Gilead Sciences (formerly NeXstar).
DaunoXome, was administered as a single, 1h infusion on day 1.
Where there was recovery from toxicity and no disease progres-
sion, treatment cycles were repeated every 21 days. In cases of DLT
for the first cycle, patients were treated at the previous dose level
for subsequent cycles. Patients were allowed up to a maximum of
12 courses of treatment.
Recruitment/dose escalation
Two cohorts of patients were recruited, given an anticipated
reduction in bone marrow reserve for patients who had undergone
intensive chemotherapy
  Arm A – patients who relapsed after conventional therapy.
  Arm B – patients previously treated with craniospinal radio-
therapy and/or high dose therapy.
High-dose therapy was defined as any procedure that required
bone marrow or stem cell rescue after chemo- or radiotherapy.
Patients were not stratified according to prior anthracycline
exposure.
Dose limiting toxicity was defined from the safety profile of
cycle one. No within-patient dose escalation was allowed,
according to the method of Korn et al (1994). Three patients were
recruited in each arm at each dose level until DLT was reached. If a
single DLT was seen in one cohort, a maximum of three additional
patients were recruited at that level. If DLT was not observed in
these additional patients, then the next dose level was entered. The
MTD was defined as that dose level immediately below the dose
level at which a minimum of two patients in a cohort of three to six
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spatients experienced DLT. A total of six patients were treated at the
MTD to assess toxicity fully.
Evaluation during treatment
Full blood counts and biochemistry tests including liver function
were performed twice weekly (for courses 1 and 2, weekly for
subsequent courses). Physical examination and vital signs were
assessed weekly. Cardiac toxicity was assessed on day 21 of each
cycle by Echo and ECG. Assessment of tumour burden was made at
baseline, after two cycles, and after every other cycle. All imaging
performed on any patient showing response was reviewed by two
radiologists. The following definitions were used for response:
  Complete response (CR)¼no radiological evidence of residual
tumour on MRI scan,
  Partial response (PR)¼450% reduction of the product of two
maximum perpendicular diameters of the tumour,
  Stable disease (s.d.)¼o25% reduction of the product of two
maximum perpendicular diameters of the tumour without
radiological evidence of tumour progression or dissemination,
  Progressive disease (PD)¼any radiological or clinical evidence
of tumour progression, or any new tumour site.
Toxicity Toxicity was graded according to the NCI Common
Toxicity Criteria (CTC) 1998 (version 1) or, where this was not
possible, according to severity (i.e. mild, moderate, severe or life
threatening).
A DLT was defined during the 21 days after the first dose of
DaunoXome as follows:
1. Myelosuppression: CTC grade IV neutropenia, thrombocyto-
penia or leucopenia lasting at least 7 days.
2. Cardiac: 420% fall in the ejection fraction at day 21 compared
with initial values,
3. Clinically relevant nonhaematological CTC grade III or IV.
As a result of discussions regarding cardiac toxicity seen in
some early patients, the definition of dose limiting cardiac toxicity
was revised during the study. A single recorded fall of 20% in the
ejection fraction at day 21 was defined initially as a DLT. Wide
intrapatient variability was recorded in some patients, and concern
was raised that an inappropriately low MTD may be identified if
such changes were not representative of cardiac function. Indeed,
two patients with a fall in ejection fraction at day 21 showed
complete recovery of cardiac function at day 28. In consultation
with cardiologists in France and the UK, a decision to require a
sustained reduction in cardiac function (EF) of 20% was made, and
therefore a repeat echocardiogram was performed at day 28 in any
patient with a possible cardiac DLT. All cardiac toxicities were
reported as Serious Adverse Events to the UKCCSG Data Centre.
Dose limiting toxicity and MTD were determined using
DaunoXome alone, and subsequently with G-CSF support
(Filgrastim 5mcgkg
 1day
 1). Patients with evidence of clinical
progression discontinued after one course. Full evaluation of
tumour response was undertaken after the second course. Patients
with response or stable disease were eligible to continue
DaunoXome for further disease assessment at the same dose,
provided no DLT occurred. If a DLT occurred, patients were
treated at one dose level below for subsequent cycles.
RESULTS
Patient characteristics
A total of 48 patients were enrolled into the study: an additional
two patients were registered, but did not receive any treatment.
Five patients were not evaluable for haematological toxicity at the
end of cycle 1, but were eligible for cardiac toxicity. Three of the 48
patients were not evaluable for cardiac toxicity, because of failure
to monitor after the first cycle of chemotherapy (patient unwell or
refusal to allow monitoring).
Patient characteristics are summarized in Table 1. Arm A
recruited more patients with brain tumours and a slight
predominance of male patients (ratio of 1.4:1).
Drug administration
Arm A patients were treated at five dose levels (dose (number)): 80
(2 – one patient eligible from arm B), 100 (3), 125 (8), 155 (7), 190
(7) mgm
 2 per cycle (total 27 patients, 5 not fully evaluable). Arm
B patients were treated at three dose levels, 80 (3), 100 (7), 125 (3)
mgm
 2 per cycle (total 13 patients, two not fully evaluable). Arm B
patients with G-CSF were treated at 125 (3), 155 (3) and 190 (2)
mgm
 2 per cycle (total eight patients, one not fully evaluable). A
total of 98 courses of DaunoXome were given in the whole study, a
median of two courses per patient (range 1–8).
Adverse events
An adverse event was defined as any CTC grade III or IV toxicity that
occurred at any time while the patient was on study. Cardiac toxicity
of any grade was reported. Serious adverse events were defined as:
  Death occurring within 30 days after the last study drug
administration.
  Any event which was life threatening, incapacitating or
permanently disabling, or required prolonged hospitaliation.
  Clinical or laboratory events which require withdrawal of the
drug.
Nonhaematological toxicities
Adverse events were reported for all children. In all, 38 reported
adverse events as possibly, probably or definitely related to the
study drug after 1 cycle.
A total of 260 nonhaematological adverse events (excluding
cardiac toxicity) were reported during cycle 1. In all, 125 of these
were classed as possibly, probably or definitely drug related
(Table 2).
A total of 20 nonhaematological SAEs classed as possibly,
probably or definitely related were reported in 17 patients during
cycle 1. Many of these were related to coincident haematological
toxicity.
Two patients developed allergic reactions to DaunoXome at
the time of drug administration during cycle 1. Both patients
developed a high temperature, one developed a generalised rash,
and one developed chest tightness and flushing. In both cases, the
drug was later restarted without further adverse event. One other
patient developed a high temperature and a generalised maculo-
papular exanthema shortly after the start of treatment during cycle
2. These symptoms disappeared under treatment after 2h.
Administration was completed slowly thereafter.
Haematological toxicity
The DLT was haematological for patients treated in arm A and B
without G-CSF support (Table 3). The principal toxicity was
leucopenia and neutropenia, although thrombocytopenia was
dose-limiting for one patient treated at 190mgm
 2 in Arm
BþG-CSF. The median time (range) to recovery of neutrophils
(41 10
9l
 1) for each arm over the whole range of administered
doses were: Arm A 23 days (14–28), Arm B 25 days (19–26), Arm
BþG-CSF 18 days (0–24).
The MTD of DaunoXome was 155mgm
 2 in Arm A
and 100mgm
 2 in arm B. Recruitment of patients in Arm B with
G-CSF support was suspended at a time when two patients had
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sbeen enrolled at the 190mgm
 2 level, one of whom had shown
grade IV haematological toxicity.
Haematological toxicity was not generally greater following
second or subsequent doses of DaunoXome. Greater CTC toxicity
was seen in only in only two patients.
Cardiac toxicity
An unexpectedly high rate of cardiac toxicity – 14/48 patients –
was found. An additional patient experienced cardiac toxicity
following a second ‘off study’ course of DaunoXome. Of these
15 patients, seven experienced CTC grade I, five grade II, two
grade III and one grade IV. There was no cardiac toxicity seen in
patients who received a cumulative dose (native anthracyclines
and DaunoXome) of o240mgm
 2 anthracycline, but no correla-
tion beyond this was seen between the grade of toxicity and total
exposure to anthracycline in this study (Figure 1). A summary of
cardiac toxicity is given in Table 4.
In 13/15 cases, grade 1–IV cardiac toxicity was thought to be at
least possibly related to the study drug. In one patient, toxicity was
probably due to a symptomatic pericardial effusion, attributable
to underlying disease. One other patient had a pericardial effusion
(grade I toxicity) unrelated to DaunoXome.
In all, 13 of 15 patients had received prior anthracyclines, with
cumulative doses from 60 to 420mgm
 2 (median 200mgm
 2). In
all, 15 of 30 patients evaluable for cardiac toxicity who did NOT
develop cardiac toxicity, had received previous anthracycline (dose
range 117–450, median 243mgm
 2). There was a trend towards
increased toxicity in the group with prior anthracycline exposure
(P¼0.0523, Fisher’s Exact test).
In all, 10 of 15 patients with cardiac toxicity had previously
received radiotherapy (three directly to the chest and one had total
body irradiation). Four patients without cardiotoxicity had
received prior radiotherapy to the chest, and one had received
TBI. There was no statistically significant difference in cardiac
toxicity between these two populations (P¼0.40, w
2 test). The
small numbers for patients treated with prior radiotherapy to the
chest meant that no statistical difference could be identified
(OR¼2.4, 95% CI: 0.5–11.2).
Three patients experienced unrelated or transient cardiac
abnormalities at the end of cycle 1. One patient showed a fall in
Fractional Shortening (FS) from 38 to 29% after a single dose of
80mgm
 2. This patient was reported to have normal cardiac
function, but had a pericardial effusion secondary to progressive
metastatic disease. This change was considered to be related
exclusively to disease. One patient showed a fall of FS from 35 to
28% (20% reduction) after a single dose of 80mgm
 2. The
Table 1 DaunoXome patient characteristics
Arm A (no G-CSF)
Arm B
(no G-CSF)
Arm B
(with G-CSF)
Total
numbers
Total number entered 27 13 8 48
Total number evaluable for cardiac toxicity 25 12 8 45
Total number evaluable for haematological toxicity 24 12 7 43
No. of males 14 8 6 28
No. of females 13 5 2 20
Age (years) median (Range) 10.0 (1.3–18.4) 8.5 (1.9–18.5) 9.7 (4.2–11.1) 9.6 (1.3–18.5)
Diagnosis Osteosarcoma 5
Rhabdomyosarcoma 2
PNET 2
Glioma 5
Ewings 1
Astrocytoma 2
Ependymoma 2
NHL 1
Neurosarcoma 1
Hodgkins 1
Undiff nasopharngeal ca 1
Hepatocellular carcinoma 1
Malignant germinal tumour 1
Malignant adrenal cortical carcinoma 1
Choroid plexus carcinoma 1
Neuroblastoma 4
Synovial sarcoma 2
Medulloblastoma 1
Spinal PNET 1
Osteosarcoma 1
Ewings 1
PPNET 1
Hodgkins 1
Anaplastic Ependymoma 1
Neuroblastoma 4
Clear cell sarcoma 1
Rhabdomyosarcoma 1
Medulloblastoma 1
Nephroblastoma 1
Prior therapy
Chemotherapy
a 22 12 8 42
Radiotherapy 17 6 4 27
Surgery 21 11 8 40
No. of patients previously treated with anthracyclines 15 8 8 31
Median prior anthracyclines dose (mg) 0 88 224
No. of patients who previously had RT that affected the chest 4 2 (1 TBI) 3 (1 TBI) 9
aMay have had more than one previous chemotherapy treatment. Abbreviation: TBI, Total body irradiation.
Table 2 Non-haematological toxicities
Toxicity Episodes Patients
Fever or infection 30 24
Nausea and/or vomiting 19 16
Rash/bruising 5 3
Alopecia 2 2
Allergic reaction to DaunoXome 2 2
Mucositis 3 3
Biochemical change 31 11
Pain 9 7
Other 24 16
Total 48
Data for all cycles (n¼98) are included.
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sechocardiogram was reported to be otherwise normal, and one
week later, repeat echocardiography showed FS to be 36%. This
change in function was felt to be a drug-related toxicity but was
transient. One further patient suffered a cardiac DLT after a single
dose of 125mgm
 2, with a reduction in Ejection Fraction (EF) by
more than 20% (74 to 54%). A repeat echocardiogram one week
Table 3 Haematological toxicity – cycle 1 data only
Maximum toxicity grade reported
Neutrophils Leukocytes Platelets Haemoglobin
Dose (mgm
 2) No. evaluable/No. courses 3 4 3 4 3 4 3 4
Arm A
80 2/2 1 0 1 0 0 1 1 0
100 3/3 1 1 0 1 0 0 0 0
125 7/8 3 4 5 2 1 1 2 0
155 6/7 0 6 3 3 1 0 0 0
190 6/7 0 6 0 6 2 1 3 1
Arm B
80 3/3 1 2 2 0 2 0 1 0
100 7/7 2 5 2 3 2 3 4 1
125 2/3 0 2 0 2 0 1 0 0
Arm B+G-CSF
125 3/3 0 1 0 1 1 2 0 0
155 3/3 1 2 3 0 0 2 1 0
190 1/2 0 1 0 1 0 1 0 0
Numbers refer to the maximum grade of toxicity experienced, but duration is not considered.
Table 4 Summary of cardiac toxicity identified
Baseline
Patient
number
Dose
(mgm
 2)F S E F
Course
number
CTC
grade Toxicity Causality Resolution?
Previous anthracyclines/
Chest RT
1 80 35 1 I Day 21 FS¼28% Possibly Day 28, FS¼36%, overall
function ‘good’
Doxorubicin 150mgm
 2
3 80 38 76 1 I–II Day 21 small pericardial
effusion
Possibly Proceeded to second
course
Doxorubicin 148.6mgm
 2
2 III Cycle 2 day 24 Echo
FS¼26%, EF¼59%
Unlikely No. Effusion related to
metastatic disease.
7 125 42 74 1 II Day 21 FS¼27%, EF¼54%
(drop of 27%)
Related Yes. Day 28 FS¼40%
EF¼72%
Doxorubicin 150mgm
 2
13 125 40 70 1 I Day 21 EF¼57% (fall of
18.6%)
Related Yes. Day 28, FS¼36%,
EF¼74%
Doxorubicin 344mgm
 2
14 125 39 77 1 II Day 21 EF¼61% (fall of
20.1%
Related Yes. Day 36 FS¼40%,
EF¼70%
No
19 155 30 66 2 II Day 21 cycle 2 23.10.00
FS¼30% EF¼67% 8.11.00
FS¼27.5%, EF¼62%
15.11.00 FS¼20.18%,
EF¼49%
Related No further echo Doxorubicin 200mgm
 2
20Gy RT to chest
21
a 155 4 IV Cycle 4 EF 24%, FS 24% Related No Epiadriamycin 198mgm
 2
25 190 32 66 3 I Day 21 FS¼29% Probable Yes. Day 28 FS¼30% Doxorubicin 147mgm
 2
104 100, 80 (X3) 30 63 4 IV Cycle 4 FS¼20%, EF¼49% Probable No. Patient died:
congestive cardiac failure
Adriamycin 328mgm
 2,
45Gy to spine and left lung
107 100 30 67 1 I Small pericardial effusion Unlikely Yes. Echo subsequently
normal FS 41% EF 73%
Doxorubicin 420mgm
 2
114 125, 100
(X6)
49 80 8 II Cycle 8, day 21 FS¼25%,
EF¼58%
Related No No
112 125 32 60 1 I Cycle 1, day 21 FS¼27%,
EF¼53%
Probable Patient withdrawn from
study
Doxorubicin 202mgm
 2
302 125+GCSF 37 68 2
a II Cycle 2, day 21 FS¼25%,
EF¼50%
Possibly Progressive disease, no
further echo. No clinical
symptoms
Adriamycin 288mgm
 2
304 155+GCSF 34 63 2 I Cycle 2, day 21 FS¼29% Probable Yes Doxorubicin 61mgm
 2,
Epirubicin 150mgm
 2
305 155+GCSF 34 63 1 I Cycle 1, day 21 FS¼29% Probable No further echo Idarubicin 10mgm
 2, Total
body irradiation (12Gy)
aOff study. Abbreviations: FS, Fractional shortening. EF, Ejection Fraction.
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slater showed normal cardiac function, (FS 40%, EF 72%), and the
treating physician elected to continue with DaunoXome off-study
on a compassionate basis. Cardiac function after this cycle
remained normal. A further cohort of patients was recruited at
the same dose level, with no further cardiac toxicity.
The results from these three patients prompted a review of
criteria for the assessment of cardiac toxicity. There was a concern
that transient falls in measured cardiac function were not
representative of true changes in function, and that an inappro-
priately low MTD might therefore be identified. A protocol
modification was made, such that cardiac toxicity would be
evaluated at 21 days and, if abnormal, a second evaluation would
be made at day 28. Only if cardiac function were still abnormal,
measured by an absolute FS of o29% or a change in EF by X20%,
would cardiac DLT be reportable.
In fact, no further patient developed a cardiac DLT after the first
cycle of DaunoXome, at day 21 or day 28, and this modification to
the protocol did not, therefore, affect the outcome of the study.
Significant cardiac toxicity was identified, however, in three
patients who received repeated courses of DaunoXome. One
patient, who had received no prior anthracycline chemotherapy,
developed a reduced EF (a fall of 28% from 80 to 58%) after eight
cycles, and a cumulative anthracycline dose of 825mgm
 2. The
ejection fraction recovered to 63% 1 week later, and the patient
showed full recovery 1 month later (EF 70%). No further
anthracycline was given. This patient eventually died of disease
progression 3 years after entry into the study.
One patient, who had received radiotherapy to the left lung and
spine, and a prior anthracycline dose of 328mgm
 2, received four
cycles of DaunoXome without cardiac toxicity. After the fourth
cycle, a rapid, and eventually fatal deterioration in cardiac function
developed. Autopsy confirmed cardiomyopathy consistent with
anthracycline toxicity. This patient received a cumulative
anthracycline dose of 668mgm
 2 (340mgm
 2 of which was
DaunoXome).
One patient developed rapidly progressive cardiac impairment
after four cycles of DaunoXome (dose level 155mgm
 2), and died
as a result of cardiac failure. This patient had received a cumulative
anthracycline dose of 818mgm
 2 (620mgm
 2 of which was
DaunoXome).
As a result of these two deaths in patients with repeated dosing,
recruitment into the study was suspended, pending review of
patient data. The trial was subsequently closed before the
conventionally defined MTD had been identified for patients with
G-CSF support in Arm B.
Pharmacokinetics
Pharmacokinetic analysis was performed for a total of 31 patients,
(five at 80mgm
 2, five at 100mgm
 2, eight at 125mgm
 2, nine
at 155mgm
 2, four at 190mgm
 2). The AUCs of the three
compounds were evaluated by the trapezoidal rule. Pharmaco-
kinetic parameters are given in Table 5. Typical pharmacokinetic
profiles for each anthracycline species are given in Figure 2.
Measured parameters for DaunoXome were similar to those
reported previously (Bellott et al, 2001). Liposomal Daunorubicin
showed one-compartment elimination kinetics in all patients, and
parameters were not dose-dependent. Total plasma clearance was
(mean7s.d.): 0.42370.220lh
 1m
2, the elimination half-life
5.5571.07h, and the total volume of distribution 3.4772.49lm
 2.
Free daunorubicin (DNR) was seen in plasma in most patients at
the end of DaunoXome infusion, although the peak concentration
(Cmax) was delayed by 2–4h in 10 patients. It had essentially the
same pharmacokinetic behaviour as free administered dauno-
rubicin. Free daunorubicin followed biexponential elimination
kinetics in most patients; in six, a mono-exponential curve better
described the observed data. The elimination half-life of free
daunorubicin was independent from the dose administered. Its
mean value in the overall population was 11.373.9h.
Daunorubicin was converted to daunorubicinol which reached
its maximal plasma concentration 7–24h after the onset of
DaunoXome infusion and was eliminated with mono-exponential
decay with a half-life of 17.675.2h, independent of administered
dose.
No significant difference in the pharmacokinetic parameters of
the three compounds was exhibited between patients included in
arm A or in arm B.
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The AUCs of the three compounds analysed are shown as a
function of the dose administered in Figure 3. DaunoXome AUC
correlated only poorly with administered dose, and no significant
difference in AUCs of liposomal daunorubicin, free daunorubicin
and daunorubicinol was seen at doses of 80, 100 and 125mgm
 2
(Figure 4).
The ratio of AUCs of free daunorubicin to liposomal daunor-
ubicin varied between 0.1 and 0.2 in most patients. A statistically
greater conversion of liposomal to free daunorubicin was seen at
the highest dose (190mgm
 2). This higher AUC of free drug seen
at higher doses might be expected to give a nonlinear risk of
cardiac toxicity. The AUC ratio of daunorubicinol to free
daunorubicin varied for most patients between 0.05 and 0.12,
and once again, greater conversion of daunorubicin to daunor-
ubicinol was seen at the highest dose.
There was no relationship between the pharmacokinetic
parameters evaluated in these patients and their age; in addition,
the pharmacokinetic parameters in those patients who developed
cardiac toxicity or who responded to DaunoXome therapy were
close to median values for the population as a whole and could not
explain these clinical events.
Patient response to treatment
Tumour response was assessed after two cycles in 29 patients.
Response was measured by MRI in all cases. One patient was not
evaluable, six had nonmeasurable disease, seven had SD, 14 had
PD. One relapsed Primitive Neuro-Ectodermal tumour had a
partial response, which continued for four cycles. One patient with
ependymoma had stable disease for eight cycles of DaunoXome,
but developed cardiac toxicity (grade II). He died from progressive
disease, 3 years after entry into the study (Table 6).
Patient withdrawal from study
In all, 39 patients were withdrawn from study due to treatment
failure, three because of cardiac adverse events, one because of
neurological deterioration (PD), one because they died (PD). One
patient was withdrawn so that drug could be given compassio-
nately at a different hospital, one to have surgery, one because of a
protocol violation and one because of drug shortage.
DISCUSSION
The development of new therapies in paediatric oncology remains
slow for several reasons. There is a limited supply of new drugs
suitable for development. Due to small numbers of patients, phase
I and II studies are slow to run, and ethical concerns may lead to
reluctance to enroll young patients. It is clear, however, that in
childhood, toxicities may be different from those in adults (Doz
et al, 2001) and that the tolerance of children may be better(Vassal
et al, 2003). When a DLT has been defined in adults, it should be
also defined in a paediatric cohort.
Paediatric tumours differ histologically from adult tumours, and
appear to have greater sensitivity to chemotherapy. Timing of
phase I studies in children should therefore be early, not
dependent upon results from adult studies. It is to be hoped that
new regulations in the USA and Europe will encourage early
release of new agents by industry.
Anthracyclines have demonstrated efficacy in most paediatric
tumours. Cardiotoxicity is a major concern in children, given the
expected growth of the child, and long post-treatment survival
anticipated. The reduction of cardiac toxicity of these very active
compounds would be of great benefit.
Table 5 Pharmacokinetic parameters
80 100 125 155 190 Overall
Dose (mgm
 2) Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d. Mean s.d.
AUC ((ngml
 1) h)
DaunoXome 628521 139129 1087906 352553 734347 206424 1719306 907368 1097766 349420
Daunorubicin 108206 26103 96802 21902 95966 31363 198159 86022 262881 81111
Daunorubicinol 7967 1700 11043 3021 10033 3592 15803 6219 37885 10944
Clearance (lhm
 2)
DaunoXome 0.46 0.35 0.26 0.06 0.50 0.12 0.36 0.19 0.57 0.27 0.42 0.22
Elimination half-life (h)
DaunoXome 6.94 1.49 5.36 0.23 4.93 0.47 5.25 1.05 5.93 0.46 5.55 1.07
Daunorubicin 12.63 3.82 10.22 1.50 10.94 2.81 10.13 4.17 14.66 6.35 11.34 3.90
Daunorubicinol 20.03 7.51 15.95 2.31 17.47 3.86 19.04 7.05 14.29 2.51 17.59 5.24
Volume of distribution (lm
 2)
DaunoXome 4.99 5.04 2.00 0.41 3.53 1.01 2.71 1.55 4.99 2.59 3.47 2.49
AUC ratio
Daunorubicin: DaunoXome 0.18 0.06 0.09 0.01 0.13 0.03 0.13 0.06 0.24 0.03 0.15 0.06
Daunorubicinol: Daunorubicin 0.08 0.02 0.11 0.02 0.11 0.03 0.09 0.03 0.15 0.02 0.10 0.03
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prior anthracyclines, and that the cardiac toxicity identified does
not represent the true risk associated with DaunoXome. While this
is a valid criticism, it would be unusual for patients who reach
this stage of treatment to be anthracycline-naı ¨ve, particularly in
the group who have already undergone high-dose therapy.
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tumours, as in the study of Lippens et al (Lippens, 1999). Given the
encouraging reports suggesting lack of cardiac toxicity with this
agent, it was therefore felt appropriate to include all potentially
eligible patients.
The assessment of cardiotoxicity is not well defined: there is
only poor correlation between acute and delayed cardiotoxicity,
and the significance of acute changes is therefore unknown.
Cardiac troponins have been proposed as markers of acute
myocardial damage, but their value in prediction of outcome is
still uncertain (Missov et al, 1997; Sparano et al, 2002; Auner et al,
2003). The assessment of cardiac toxicity within a phase I study is
therefore problematic, and there is no guidance in published
literature. Within the design of a phase I trial, given that patients
usually have end-stage disease, long-term follow-up is rarely
considered. It is possible that the reports from adult studies of
DaunoXome, of no cardiotoxicity even with high cumulative doses,
may therefore be misleading.
In this study, we report that liposomal anthracyclines
have an unexpectedly high rate of cardiotoxicity in children.
Whether cardiotoxicity would appear in anthracycline-naive
patients, and whether higher doses of a liposomal compound as
compared to naive compound may be delivered remains a matter
of debate.
The dose-limiting toxicity of DaunoXome without G-CSF is
neutropenia, at 155 and 100mgm
 2 for patients with conventional
or heavy previous treatment, respectively. Recruitment to Arm B
with G-CSF support was halted having recruited two patients at
190mgm
 2, with one DLT (thrombocytopenia). This was not
unexpected for the group of patients under study. In all, 30 out
of 43 patients experienced grade IV neutropenia during the first
cycle of treatment. The most significant fall in neutrophil count
occurred between 10 and 19 days following administration of
DaunoXome, but recovery was usual by day 21.
The noncardiac, nonhaematological toxicities reported were
related to myelosuppression (febrile neutropenia), but nausea,
hypermagnesaemia and allergic reaction to DaunoXome were also
seen. These toxicities were not considered excessive for patients
undergoing this treatment regime.
This is the first paediatric study with liposomal Daunorubicin
that has shown a significant degree of cardiac toxicity, albeit
with repeated dosing. Three other paediatric studies have
been performed, but none of these raised concerns over
the degree of cardiac toxicity (Baruchel, personal communication;
Lippens, 1999; Hempel et al, 2003). The treatment regimes used
in these studies differ significantly from the present study: in
both, patients were given four doses over a 4-week time period.
Patients treated in the study of Baruchel received individual
doses up to 120mgm
 2, to a maximum cumulative dose
of 720mgm
 2. In the study of Lippens (1999), patients received
individual doses of 60mgm
 2, to a maximum cumulative
dose of 600mgm
 2. In the study reported by Hempel
et al, patients received individual doses of 30–60mgm
 2 on
days 1 and 5 of each cycle. In the present study, patients received
a single dose every 21 days, up to a maximum of eight cycles.
The two patients who died as a result of DaunoXome treatment
both had high cumulative levels of anthracyclines (668 and
818mgm
 2), but not markedly different from those previously
reported.
Comparison of PK
A response rate of about 4% is often seen in phase I studies, and
where responses occur more frequently, activity of the agent is felt
to be worth exploring further. In this study, only one patient
demonstrated a partial response, after two and four cycles. One
other demonstrated a prolonged period of stable disease, for eight
cycles of chemotherapy. The response rate of one of 48 patients
(2.1%) was disappointing.
CONCLUSION
Although it was hoped that cardiac toxicity with DaunoXome
would be significantly reduced compared to conventional Daunor-
ubicin, this was not seen. Studies in anthracycline naı ¨ve patients
may still be justified, but severe cardiotoxicity in patients receiving
repeated courses of DaunoXome mean caution should be exercised
in the use of this drug in children. The possibility that DaunoXome
pharmacokinetics may change, such that a greater exposure to
anthracycline or its active metabolite is seen at higher doses, may
account for the observed cardiac toxicity in this study, but further
confirmation of this is required.
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